Endometrial carcinoma: Association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression

Virchows Archiv

Volumn 438, Issue 5, 2001, Pages 470-477

  Sivridis, Efthimios ^a   Giatromanolaki, Alexandra ^a   Koukourakis, Michael ^b   Anastasiadis, Panagiotis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Medical School   (Greece)

Author keywords

Angiogenesis; bcl 2, p53; Endometrial carcinoma; Steroid receptors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; STEROID RECEPTOR;

ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; TUMOR VASCULARIZATION;

ADENOCARCINOMA; CELL NUCLEUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035031593     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280000361     Document Type: Article

References (47)

1. 1. Bergqvist A, Ferno M (1993) Oestrogen and progesterone receptors in endometriotic tissue and endometrium: comparison of different cycle phases and ages. Hum Reprod 8:2211-2217
2. 2. Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP (1992) Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 79:95-100
3. 3. Bold RJ, Virudachalam S, McConey DJ (2000) Tamoxifen-induced apoptosis in pancreatic cancer is associated with reduction of bcl-2 content via transcriptional regulation. Proc Am Assoc Cancer Res 2726:428
4. 4. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I. Clinical and histologic correlations. Am J Clin Pathol 94:247-254
5. 5. Chambers JT, Maclusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE (1988) Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 31:65-81
6. 6. Chetty R, O'Leary JJ, Gatter KC (1995) Immunohistochemistry as a diagnostic tool. Current Diagn Pathol 2:38-45
7. 7. Creasman WT (1993) Prognostic significance of hormone receptors in endometrial cancer. Cancer 71[Suppl 4]:1467-1470
8. 8. Critchley HO, Tong S, Cameron ST, Drudy TA, Kelly RW, Baird DT (1999) Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo. J Reprod Fertil 115:389-395
9. 9. De Cicco Nardone F, Benedetto MT, Rossiello F, Bongiorno M, Iacobelli S, Mancuso S, Dell' Acqua S (1989) Hormone receptor status in human endometrial adenocarcinoma. Cancer 64:2572-2578
10. 10. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158:796-807
11. 11. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43: 175-203
12. 12. Friberg LG, Noren H (1993) Prognostic value of steroid hormone receptors for 5-year survival in stage II endometrial cancer. Cancer 71:3570-3574
13. 13. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H (1998) Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gyecol Oncol 69:220-225
14. 14. Giatromanolaki A, Sivridis E, Koukourakis MI, Harris AL, Gatter KC (1998) Bcl-2 and p53 expression in stage I endometrial carcinoma. Anticancer Res 18:3689-3693
15. 15. Giatromanolaki A, Sivridis E, Koukourakis MI, Georgoulias V, Gatter KC, Harris AL (1999) Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? Oncol Res 11:205-212
16. 16. Inoue M, Okayama A, Fujita M, Enomoto T, Sakata M, Tanizawa O, Ueshima H (1994) Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 58:14-19
17. 17. Jones RK, Searl RF, Bulmer JN (1998) Apoptosis and bcl-2 expression in nomal human endometrium, endometriosis and adenomyosis. Hum Reprod 13:3496-3502
18. 18. Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S (1995) c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 208:1067-1072
19. 19. Kauppila A, Janne O, Kujansuu E, Vihko R (1980) Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels. Cancer 46:2162-2167
20. 20. Kauppila A, Kujansuu E, Vihko R (1982) Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with a surgery, radiotherapy, and progestin. Clinical correlates. Cancer 50:2157-2162
21. 21. Kuwashima Y, Kobayashi Y, Kurosumi M, Tanuma J, Shiromizu K, Kishi K (1997) Inverse correlation between bcl-2 expression and cell growth fraction in human endometrial adenocarcinoma tissue. Anticancer Res 17:3773-3776
22. 22. Lax SF, Pizer ES, Ronnett BM, Kurman RJ (1998) Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 29:551-558
23. 23. Li SF, Shiozawa T, Nakayama K, Nikaido T, Fujii S (1996) Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 77:321-329
24. 24. Lilling G, Aviv Y, Hacohen H, Goldfinger N, Rotter V, Gur H, Sidi Y (2000) Effect of estradiol on the expression of genes down-stream to p53 in human breast cancer cell lines. Proc Am Assoc Cancer Res 2713:426
25. 25. Morris PC, Anderson JR, Anderson B, Buller RE (1995) Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol 56:406-411
26. 26. Nisolle M, Casanas-Roux F, Wyns C, de Menten Y, Mathieu PE, Donnez J (1994) Immunohistochemical analysis of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: a new quantitative method. Fertil Steril 62: 751-759
27. 27. Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyama T, Hirohashi S (1994) c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 205:73-78
28. 28. Page DL, Jensen RA (1995) Angiogenesis in human breast carcinoma: what is the question? Hum Pathol 26:1173-1174
29. 29. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY (1990) JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752-757
30. 30. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B (1994) Paradoxical inhibition of solid cell growth by bcl-2. Cancer Res 54:3714-3717
31. 31. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY (1995) HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85:729-734
32. 32. Runowicz CD, Nuchtern LM, Braunstein JD, Jones JG (1990) Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. Gynecol Oncol 38:437-441
33. 33. Saegusa M, Kamata Y, Isono M, Okayasu I (1996) Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 180:275-282
34. 34. Saegusa M, Okayasu I (1997) Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol 123:429-434
35. 35. Salvesen HB, Iversen OE, Akslen LA (1998) Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 77:1140-1144
36. 36. Save V, Sylander K, Hall PA (1998) Why is p53 protein stabilised in neoplasia? Some answers but many more questions! J Pathol 184:348-350
37. 37. Silver SA, Tavassoli FA (2000) Pleomorphic carcinoma of the breast: clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma. Histopathology 36:505-514
38. 38. Silverberg SG, Kurman RJ (1992) Endometrial carcinoma. In: Tumors of the uterine corpus and gestational trophoblastic disease. Atlas of Tumor Pathology. Third Series. Fasicle 3. Armed Forces Institute of Pathology, Washington DC, pp 47-89
39. 39. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B (1996) p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610
40. 40. Sivridis E, Buckley CH, Fox H (1987) An immunohistochemical study of steroid binding by endometrial glandular epithelial cells throughout the menstrual cycle. Br J Obstet Gynaecol 94:687-691
41. 41. Sivridis E, Buckley CH, Fox H (1993) Type I and type II estrogen and progesterone binding sites in endometrial carcinomas: their value in predicting survival. Int J Gynecol Cancer 3:80-88
42. 42. Soper JT, Christensen CW (1986) Steroid receptors and endometrial cancer. Clin Obstet Gynaecol 13:825-842
43. 43. Taskin M, Lallas TA, Barber HR, Shevchuk MM (1997) bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 10:728-734
44. 44. Wang D, Konishi I, Koshiyama M, Mandai M, Nanbu Y, Ishikawa Y, Mori T, Fujii S (1993) Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. Cancer 72:2628-2637
45. 45. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9-19
46. 46. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R (1996) Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 15:202-208
47. 47. Zapata-Benevides P, Tari AM, Lopez-Berestein G (2000) Estradiol modulates the protein expression of bcl-2 and wt-1 in human breast cancer MCG-7 cells. Proc Am Assoc Cancer Res 2723:428